Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,一种
性
-CD52
,在免疫耐受诱导方案
显著,需要最少的免疫抑制维持药物.
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,一种
性
-CD52
,在免疫耐受诱导方案
显著,需要最少的免疫抑制维持药物.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
为了降低鼠引起的超敏反应,治疗性单克隆
已由改型
,
化
发展到全
。
声明:以上例句、词性分类均由互联网资自动生成,部分未经过
工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,一种人源性
-CD52
体,在免疫耐受诱导方案中效果显著,需要最少的免疫抑制维持药物.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
为了降低鼠源体引起的超敏反应,治疗性单克隆
体已由改型
体,人源化
体发展到全人
体。
声明:以上、词性分类均由
资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿,一种人源
-CD52
体,在免疫耐受诱导方案中效果显著,需要最少的免疫抑制维持药物.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
为了降低鼠源体引起的超敏反应,治疗
克隆
体已由改型
体,人源化
体发展到全人
体。
声明:以上例句、词均由互联网资源自动生成,部
未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,
人源
-CD52
体,在免疫耐受诱导方案中效果显著,需要最少的免疫抑制维持药物.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
为了降低鼠源体引起的超敏反应,治疗
单克隆
体已由改型
体,人源化
体发展到全人
体。
声明:以上例、词
分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,一种人源性
-CD52
,在免疫耐受诱导方案中效果显著,需
的免疫抑制维持药物.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
为了降低鼠源引起的超敏反应,治疗性单克隆
改型
,人源化
发展到全人
。
声明:以上例句、词性分类均互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑,一种人源性
-CD52
体,在
耐受诱导方案中效果显著,需要最少的
制维持药物.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
为了降低鼠源体引起的超敏反应,治疗性
体已由改型
体,人源化
体发展到全人
体。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,一种人源性
-CD52
,在免疫耐受诱导方案中效果显著,需
的免疫抑制维持药物.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
为了降低鼠源引起的超敏反应,治疗性单克隆
改型
,人源化
发展到全人
。
声明:以上例句、词性分类均互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,一种人源性
-CD52
体,在免疫耐受诱导方案中效果显著,需要最少的免疫抑制维持药
.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
降低鼠源
体引起的
应,治疗性单克隆
体已由改型
体,人源化
体发展到全人
体。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,一种人源性
-CD52
,在免疫耐受诱导方案中效
,需要最少的免疫抑制维持药物.
Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.
为了降低鼠源引起的超敏反应,治疗性单克隆
已由改
,人源化
发展到全人
。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。